FDA Approval Alert: The Need-to-Know | Tislelizumab/Chemotherapy in Unresectable or Metastatic PD-L1+ ESCC

In March 2025, the FDA approved tislelizumab-jsgr plus platinum-based chemotherapy as a frontline therapy for adult patients with unresectable or metastatic PD-L1–positive esophageal squamous cell carcinoma.

Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.
FDA Approves Frontline Tislelizumab/Chemo in Advanced PD-L1+ ESCC
Article
Mar 4, 2025 2:02 PM
Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.